|
|
|
|
|
|
by nextos
737 days ago
|
|
|
In practice, maybe not, but Novo Nordisk's current market cap is much bigger. In terms of revenue, I think they are on the same order of magnitude? Novo Nordisk might return to a more realistic market cap once other GLP-1 agonists enter the market, e.g. Lilly's. |
|
|